3-{2-[5-chloro-2-(benzyloxy)phenyl]cyclopent-1-enyl}benzoic acid

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 二苯乙烯类
• 英文名称: 3-{2-[5-chloro-2-(benzyloxy)phenyl]cyclopent-1-enyl}benzoic acid
• 英文别名: 3-(2-(2-(Benzyloxy)-5-chlorophenyl)cyclopent-1-enyl)benzoic acid；3-[2-(5-chloro-2-phenylmethoxyphenyl)cyclopenten-1-yl]benzoic acid
• 化学式: C₂₅H₂₁ClO₃
• 分子量: 404.893
• InChiKey: BHIIXYUVEXKWSO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.9
• 重原子数：
  29
• 可旋转键数：
  6
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.16
• 拓扑面积：
  46.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  4-氯-2-碘苯甲醚, 在 四(三苯基膦)钯 sodium hydroxide 、 sodium thiomethoxide 作用下， 以 乙二醇二甲醚 、 乙醇 、 水 、 甲苯 为溶剂， 生成 3-{2-[5-chloro-2-(benzyloxy)phenyl]cyclopent-1-enyl}benzoic acid
  参考文献：
  名称：

  The discovery of 6-[2-(5-chloro-2-{[(2,4-difluorophenyl)methyl]oxy}phenyl)-1-cyclopenten-1-yl]-2-pyridinecarboxylic acid, GW848687X, a potent and selective prostaglandin EP1 receptor antagonist for the treatment of inflammatory pain

  摘要：

  The discovery of a series of selective EP1 receptor antagonists based on a 1,2-diaryleyclopentene template is described. After defining the structural requirements for EP1 potency and selectivity, heterocyclic rings were incorporated to reduce logD and improve in vitro pharmacokinetic properties. The 2,6-substituted pyridines and pyridazines gave an appropriate balance of potency, in vivo pharmacokinetic properties and a low potential for inhibiting a range of CYP450 enzymes. From this series, GW848687X was shown to have an excellent profile in models of inflammatory pain and was selected as a development candidate. (c) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2006.10.041

文献信息

• [EN] (2-((2-ALKOXY) -PHENYL) -CYCLOPENT-1-ENYL) AROMATIC CARBO AND HETEROCYCLIC ACID AND DERIVATIVES<br/>[FR] ACIDE (2-((2-ALCOXY) -PHENYL) -CYCLOPENT-1-ENYL) AROMATIQUE CARBOCYCLIQUE AND HETEROCYCLIQUE ET SES DERIVES
  申请人：GLAXO GROUP LTD

  公开号：WO2003084917A1

  公开（公告）日：2003-10-16

  Compounds of formula (I) or a pharmaceutically acceptable derivative thereof: (I) wherein A, R1 , R2 , Rx , R8 , R9 and n are as defined in the specification, a process for the preparation of such compounds, pharmaceutical compositions comprising such compounds and the use of such compounds in medicine.

  式(I)或其药学上可接受的衍生物的化合物：其中A、R1、R2、Rx、R8、R9和n如规范中所定义，一种制备这种化合物的方法，包括这种化合物的药物组合物以及这种化合物在医学上的用途。
• (2-((2-alkoxy)-phenyl)-cyclopent-1enyl) aromatic carbo and heterocyclic acid and derivatives
  申请人：Giblin Paul Gerard Martin

  公开号：US20050239802A1

  公开（公告）日：2005-10-27

  Compounds of formula (I) or a pharmaceutically acceptable derivative thereof: wherein A, R 1 , R 2 , R x , R 8 , R 9 and n are as defined in the specification, a process for the preparation of such compounds, pharmaceutical compositions comprising such compounds and the use of such compounds in medicine.

  公式（I）的化合物或其药学上可接受的衍生物：其中A，R1，R2，Rx，R8，R9和n如规范中所定义，制备这种化合物的过程，包括这种化合物的制药组合物以及在医学中使用这种化合物的用途。
• (2-((2-alkoxy)-phenyl) -cyclopent-1enyl) aromatic carbo and heterocyclic acid and derivatives
  申请人：Glaxo Group Limited

  公开号：US07232821B2

  公开（公告）日：2007-06-19

  Compounds of formula (I) or a pharmaceutically acceptable derivative thereof: wherein A, R1, R2, Rx, R8, R9 and n are as defined in the specification, a process for the preparation of such compounds, pharmaceutical compositions comprising such compounds and the use of such compounds in medicine.

  公式（I）化合物或其药学上可接受的衍生物，其中A，R1，R2，Rx，R8，R9和n的定义如规范中所述，制备这种化合物的过程，包含这种化合物的药物组合物以及在医学上使用这种化合物的用途。
• US7232821B2
  申请人：——

  公开号：US7232821B2

  公开（公告）日：2007-06-19